NIDA CTN Mid Southern Node

Mid Southern Node of the NIDA Clinical Trials Network

litzy wu
Li-Tzy Wu, ScD, RN, MA

Duke-Kannapolis is excited to be part of the Mid Southern NIDA Node, a primary care practice-based research network that offers access to patient populations and clinicians who are interested in engaging in research projects and using Electronic Health Records (EHR) for research. The Mid Southern Node gained official recognition in September 2015, joining 12 other NIDA Clinical Trials Network nodes.

Dr. Li-Tzy Wu, Professor of Psychiatry and Professor of Medicine, is the Contact Node Principal Investigator and Director of the Mid Southern Node. Ms. Kimberly (Micki) Roseman is the Node Coordinator. 

Collaborators nida nodeinclude Duke University (Li-Tzy Wu, ScD, RN, MA,; Rowena Dolor, MD), Carolinas Healthcare System (Hazel Tapp, PhD; Oleg Tcheremissine, MD), University of North Carolina at Chapel Hill (Jacqueline R. Halladay, MD, MPH; Katrina Donahue, MD, MPH; Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM), and Vanderbilt University (Hilary Tindle, MD, MPH).

Current protocol involvements of the Mid Southern Node include:

  • EHR-DARE – CTN 0071 (Duke PI: Li-Tzy Wu, ScD) The Electronic Health Records Data Elements Research study was approved July 2016 and is projected to begin in August 2016. Researchers aim to identify EHR data available at healthcare facilities within the CTN in order to address critical barriers in substance use disorder research. This promises to advise planning future studies and improve research infrastructure. The target participants for this study will be researchers, clinicians, and IT professionals affiliated with each of the 13 CTN nodes.
  • Pharm-OUD-Care – CTN-0075 (Duke PI: Li-Tzy Wu, ScD) This study, Physician-Pharmacist Collaboration in the Management of Patients with Opioid Use Disorder, will explore the feasibility and acceptability of transitioning office-based buprenorphine treatment (OBBT) of adult patients with opioid use disorder (OUD) from physicians to pharmacists.  Study participants, buprenorphine prescribing physicians, and pharmacists will be compensated properly for their time and contribution.

    This new CTN-0075 protocol is seeking buprenorphine providers (physicians) and community pharmacists in North Carolina to participate in this study. Recruitment for participants is expected to start in late summer or fall.  To learn more about the opportunity to participate in this study, contact research coordinator Ms. Micki Roseman (micki.roseman@duke.edu), or principal investigator Dr. Li-Tzy Wu, ScD, RN (litzy.wu@duke.edu).

Past protocol involvements of the Mid Southern Node include:

  • SBIRT-PC – CTN 0057 (Duke PI: Li-Tzy Wu, ScD) Screening, Brief Intervention, and Referral to Treatment in Primary Care (SBIRT-PC) was an add-on study to provide tobacco, alcohol and other drug screening, brief intervention, and referral to treatment for a primary care high risk diabetic population.  Enrollment is now closed, and Duke staff completed follow-up visits in June 2016. Study staff will begin working on publications soon.
  • TAPS Tool – CTN 0059  (Duke PI: Li-Tzy Wu, ScD) The Tobacco, Alcohol, Prescription Medications, and Substance Use/Misuse Brief screen/assessment tool was administered to 2,000 primary care patients to test efficacy. Duke participated in enrollment as part of the Southern Consortium Node prior to gaining node status. Enrollment was completed in April 2015, the primary outcome manuscript was published in Annals of Internal Medicine.

Publications:

  1. McNeely J, Wu LT, Subramaniam G, Sharma G, Cathers LA, Svikis D, Sleiter L, Russell L, Nordeck C, Sharma A, O’Grady KE, Bouk LB, Cushing C, King J, Wahle A,  Schwartz RP. Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care Patients. Annals of Internal Medicine. 2016 Nov 15; 165(10): 690-699. doi: 10.7326/M16-0317
  2. Wu LT. Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug and Alcohol Dependence. Available online 19 October 2016. http://www.sciencedirect.com/science/article/pii/S0376871616309504
  3. Wu LT, McNeely J, Subramaniam GA, Sharma G, VanVeldhuisen P, Schwartz RP. Corrigendum to “Design of the NIDA clinical trials network validation study of tobacco, alcohol, prescription medications, and substance use/misuse (TAPS) tool” [Contemporary Clinical Trials. 2016 Jul. 19; 50: 90-97]. Contemp Clin Trials. 2016 Sep 22. pii: S1551-7144(16)30285-3. doi: 10.1016/j.cct.2016.09.001. PubMed PMID: 27665683.
  4. McNeely J, Wu LT, Subramaniam G, Sharma G, Cathers LA, Svikis D, Sleiter L, Russell L, Nordeck C, Sharma A, O’Grady KE, Bouk LB, Cushing C, King J, Wahle A,  Schwartz RP. Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care Patients. Ann Intern Med. 2016 Sep 6. doi: 10.7326/M16-0317. PubMed PMID: 27595276.
  5. Wu LT, McNeely J, Subramaniam GA, Sharma G, VanVeldhuisen P, Schwartz RP. Design of the NIDA clinical trials network validation study of tobacco, alcohol,  prescription medications, and substance use/misuse (TAPS) tool. Contemp Clin Trials. 2016 Sep;50:90-7. doi: 10.1016/j.cct.2016.07.013. PubMed PMID: 27444426;  PubMed Central PMCID: PMC5035619.
  6. Zhu H, Wu LT. Trends and Correlates of Cannabis-involved Emergency Department Visits: 2004 to 2011. J Addict Med. 2016 Aug 29. PubMed PMID: 27574753.
  7. Mannelli P, Wu LT. Primary care for opioid use disorder. Subst Abuse Rehabil. 2016 Aug 16;7:107-9. doi: 10.2147/SAR.S69715. PubMed PMID: 27574479; PubMed Central PMCID: PMC4993411.
  8. Wu LT, Zhu H, Swartz MS. Trends in cannabis use disorders among racial/ethnic population groups in the United States. Drug Alcohol Depend. 2016 Aug 1;165:181-90. doi: 10.1016/j.drugalcdep.2016.06.002.
  9. Mannelli P, Wu LT. Family substance use screening: less to hide, more to gain. Indian J Med Res. 2016 Jun;143(6):682-684. doi: 10.4103/0971-5916.191920. PubMed PMID: 27748291.
  10. Wu LT, Brady KT, Spratt SE, Dunham AA, Heidenfelder B, Batch BC, Lindblad R, VanVeldhuisen P, Rusincovitch SA, Killeen TK, Ghitza UE. Using electronic health record data for substance use Screening, Brief Intervention, and Referral to Treatment among adults with type 2 diabetes: Design of a National Drug Abuse Treatment Clinical Trials Network study. Contemp Clin Trials. 2015 Nov 10;46:30-38. doi: 10.1016/j.cct.2015.11.009. [Epub ahead of print] PubMed PMID: 26563446.
  11. Gryczynski J, Nordeck C, Mitchell SG, O’Grady KE, McNeely J, Wu LT, Schwartz RP. Reference periods in retrospective behavioral self-report: A qualitative investigation. Am J Addict. 2015 Nov 6. doi: 10.1111/ajad.12305. [Epub ahead of print] PubMed PMID: 26541893.
  12. Wu LT, Ghitza UE, Batch BC, Pencina MJ, Rojas LF, Goldstein BA, Schibler T, Dunham AA, Rusincovitch S, Brady KT. Substance use and mental diagnoses among adults with and without type 2 diabetes: Results from electronic health records data. Drug Alcohol Depend. 2015 Nov 1;156:162-9. doi: 10.1016/j.drugalcdep.2015.09.003. Epub 2015 Sep 12. PubMed PMID: 26392231.
WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly.